Sign inJoin waitlistJoin the waitlist

Joseph Cioccio

Associate Program Director · Penn State Milton S Hershey Medical Center

Credentials: · · · ·

History

Penn State Milton S Hershey Medical Center
Present
Penn State Milton S Hershey Medical Center
Present

Hematology and Medical Oncology
Penn State Milton S Hershey Medical Center
2020–2022
Internal Medicine
Penn State Milton S Hershey Medical Center
2017–2020
Lake Erie College of Osteopathic Medicine
2012–2016

Research

Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases
Review · Expert Opinion on Investigational Drugs · 2019 · First of 2 authors · 13 citations
CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia
Frontiers in Immunology · 2023 · 10 citations
Assessment of chimerism by next generation sequencing: A comparison to STR/qPCR methods
Human Immunology · 2024 · 8 citations

Kentaro Minagawa
12 papers
Shin Mineishi
12 papers
Christopher Ehmann
11 papers
Hong Zheng
11 papers
Hiroko Shike
10 papers
KR
Kevin Rakszawski
10 papers
Myles Nickolich
10 papers
Seema Naik
10 papers
DC
David Claxton
8 papers
NS
Natt Songdej
6 papers
RG
Robert Greiner
6 papers
Witold Rybka
6 papers

Clinical trials

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Principal investigator · Recruiting · Phase 2
Milton S. Hershey Medical Center
2026–2031
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027